347 related articles for article (PubMed ID: 18455082)
1. [The PCPT trial].
Hamdy FC; Rouprêt M
Prog Urol; 2008 Apr; 18 Suppl 3():S40-3. PubMed ID: 18455082
[TBL] [Abstract][Full Text] [Related]
2. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
[TBL] [Abstract][Full Text] [Related]
3. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
[TBL] [Abstract][Full Text] [Related]
4. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
Goetzl MA; Holzbeierlein JM
Nat Clin Pract Urol; 2006 Aug; 3(8):422-9. PubMed ID: 16902518
[TBL] [Abstract][Full Text] [Related]
5. [Practical follow-up of a patient treated with finasteride in screening for prostate cancer].
Villers A
Prog Urol; 2008 Apr; 18 Suppl 3():S58-62. PubMed ID: 18455086
[TBL] [Abstract][Full Text] [Related]
6. High-grade prostate cancer and finasteride.
Lebdai S; Bigot P; Azzouzi AR
BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
[TBL] [Abstract][Full Text] [Related]
7. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
Andriole G; Bostwick D; Civantos F; Epstein J; Lucia MS; McConnell J; Roehrborn CG
J Urol; 2005 Dec; 174(6):2098-104. PubMed ID: 16280736
[TBL] [Abstract][Full Text] [Related]
8. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
[TBL] [Abstract][Full Text] [Related]
9. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
[TBL] [Abstract][Full Text] [Related]
10. Effect of finasteride on risk of prostate cancer: how little we really know.
Rubin MA; Kantoff PW
J Cell Biochem; 2004 Feb; 91(3):478-82. PubMed ID: 14755678
[TBL] [Abstract][Full Text] [Related]
11. [Contribution of the PCPT trial to finasteride treatment of micturition disorders due to benign prostatic hyperplasia].
de la Taille A
Prog Urol; 2008 Apr; 18 Suppl 3():S53-7. PubMed ID: 18455085
[TBL] [Abstract][Full Text] [Related]
12. [Relevance of chemoprevention from PCPT trial].
Irani J
Prog Urol; 2008 Apr; 18 Suppl 3():S63-5. PubMed ID: 18455087
[TBL] [Abstract][Full Text] [Related]
13. The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
Mellon JK
Eur J Cancer; 2005 Sep; 41(13):2016-22. PubMed ID: 16061372
[TBL] [Abstract][Full Text] [Related]
14. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
Reed AB; Parekh DJ
Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
[TBL] [Abstract][Full Text] [Related]
15. Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
Unger JM; Thompson IM; LeBlanc M; Crowley JJ; Goodman PJ; Ford LG; Coltman CA
Cancer; 2005 Apr; 103(7):1375-80. PubMed ID: 15739207
[TBL] [Abstract][Full Text] [Related]
16. Implementation of the Prostate Cancer Prevention Trial (PCPT).
Goodman PJ; Tangen CM; Crowley JJ; Carlin SM; Ryan A; Coltman CA; Ford LG; Thompson IM
Control Clin Trials; 2004 Apr; 25(2):203-22. PubMed ID: 15020037
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer prevention and finasteride.
D'Amico AV; Barry MJ
J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
[TBL] [Abstract][Full Text] [Related]
19. Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?
Grover S; Lowensteyn I; Hajek D; Trachtenberg J; Coupal L; Marchand S
J Urol; 2006 Mar; 175(3 Pt 1):934-8; discussion 938. PubMed ID: 16469585
[TBL] [Abstract][Full Text] [Related]
20. The cost of prostate cancer chemoprevention: a decision analysis model.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
